3 New Strong Buy Ratings from Top-Rated Analysts: 12/11/2025
By Jessie Moore, Stock Researcher and Writer
December 11, 2025 7:04 AM UTC
Here’s what top-rated analysts are loving right now:
- Dexcom (DXCM) snaps back with improving fundamentals
- Newmont Corp (NEM) benefits from a little-seen trend
- Eli Lilly & Co (LLY) is a Strong Buy despite a recent pullback
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Valuation Up 5,000%. Shares Now $0.85 - Still Early? RAD Intel has emerged as a critical player in the AI infrastructure powering digital advertising. It's already working with Fortune 1000 clients, fueling their marketing performance through a proprietary AI decision layer that delivers results-not hype. Backed by Adobe, Fidelity Ventures, and insiders from Google, Meta, and Amazon, RAD Intel has raised over $60 million and grown its valuation over 5,000% in under four years. The share price recently increased to $0.85, reflecting the company's momentum-but there's still limited allocation available. Over 14,000 investors have already moved. If you're still watching from the sidelines, now may be the time to act. View the investor brief and lock in $0.85 shares while the current allocation remains open. *This valuation has been set by RAD Intel. DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A+ offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radintel.ai.1. Dexcom (NASDAQ: DXCM)
DexCom is snapping back with improving fundamentals, surging cash flow, and major margin expansion setting the stage for a powerful rebound.
Zen Rating: B (Buy) — see full analysis
Recent Price: $65.62 — get current quote
Max 1-year forecast: $102.00
Why we're watching:
- Analyst support: DXCM currently has 13 Strong Buy ratings, 4 Buy ratings, and 3 Hold ratings from 20 total analysts we track covering the stock, reflecting confidence in the CGM market leader's recovery trajectory. See the ratings
- For example, Citigroup's Joanne Wuensch (a top 7% rated analyst) maintained her Strong Buy rating at $75, reflecting confidence in the company's long-term growth prospects despite near-term operational challenges.
- Industry ranking context: DexCom is currently the 11th highest-rated stock in the Medical Device industry — impressive considering there are 108 stocks total on the list.
- Zen Rating highlights: With its Buy (B) rating, DXCM is in a class of stocks that have historically averaged +19.88%/yr.
- Component Grades: The company shows balanced fundamentals with Value (B), Growth (B), and Financials (B) grades, while trading at an attractive valuation following recent pullback. See all 7 Zen Component Grades here
2. Newmont Corp (NYSE: NEM)
Newmont Corporation is minting cash as central-bank gold buying surges, driving record free cash flow in a powerful precious-metals macro tailwind.
Zen Rating: B (Buy) — see full analysis
Recent Price: $93.05 — get current quote
Max 1-year forecast: $125.00
Why we're watching:
- Analyst support: The Wall Street analysts we track are bullish on the stock — it has 4 Strong Buy ratings, 4 Buy ratings, and 1 Hold rating, reflecting optimism about gold's continued strength. See the ratings
- ScotiaBank's Tanya Jakusconek (a top 7% rated analyst) upgraded the stock to Buy with a $114 price target, recognizing improving operational execution and favorable commodity pricing.
- CiBC's Anita Soni (a top 6% rated analyst) upgraded Newmont to Buy with a $112 price target, highlighting the company's strengthening fundamentals and attractive valuation.
- Industry ranking context: Newmont is currently the 14th highest-rated stock out of 49 in the Gold industry, which has an Industry Rating of A. View more top gold stocks here
- Zen Rating highlights: NEM ranks in the second-highest tier of stocks we track, with an overall B (Buy) rating.
- Component Grades: Newmont showcases exceptional Financials (A) and Momentum (A) grades, with solid Value (B at 68th percentile) and Sentiment (B at 60th percentile), reflecting its strong cash generation and market positioning. See all 7 Zen Component Grades here
3. Eli Lilly & Co (NYSE: LLY)
Exceptional growth is powering this pharma heavyweight as demand for its tirzepatide-based therapies drives a blistering 54% year-over-year revenue surge.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $997.59 — get current quote
Max 1-year forecast: $1,500.00
Why we're watching:
- Analyst support: Wall Street maintains strong conviction with 8 Strong Buy ratings, 3 Buy ratings, and 3 Hold ratings from 14 total analysts we track, reflecting broad confidence in the company's diabetes and obesity franchises. See the ratings
- Morgan Stanley's Terence Flynn (a top 7% rated analyst) recently maintained his Strong Buy rating with a $1,290 price target, citing robust demand from public and private sectors with no signs of severe speculative crowding.
- Leerink Partners' David Risinger (a top 10% rated analyst) upgraded the stock to Buy with a $1,104 price target following strong Q3 results that showed EPS beat of 16.67% and revenue growth of 54% year-over-year.
- Industry ranking context: Eli Lilly is currently the 3rd highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — LLY ranks in this tier, demonstrating exceptional quality across multiple dimensions.
- Component Grades: Lilly showcases outstanding performance with Sentiment (A), Financials (B at 88th percentile), Value (B at 85th percentile), and Growth (B at 90th percentile), reflecting its dominant market position and strong execution. See all 7 Zen Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
The Quiet Company Powering the Entire AI Hardware Boom
Jabil (JBL) is an under-the-radar AI play that Smart Money is stalking. Here’s why.
3 days ago•Corbin Buff
JBL
Hot or Not, Stock Market Edition: 12/11/2025
2 stocks making waves in advance of the holidays — and 2 starting to falter. Today’s Hot or Not list includes Macy’s (M) and more.
3 days ago•Jessie Moore
M
MDB
IREN
SO
3 New Strong Buy Ratings from Top-Rated Analysts: 12/12/2025
3 Strong Buy stocks for 12/12/2025, including MongoDB (MDB) and more.
2 days ago•Jessie Moore
MDB
TTMI
KGC
3 Stocks To Watch Instead of Netflix
Forget Netflix (NFLX) … We’ve unearthed 3 tickers with even BETTER prospects. Story below.
2 days ago•Lyndon Seitz
NFLX
WBD
AENT
IMAX
UDMY
Hot or Not, Stock Market Edition: 12/12/2025
Victoria's Secret (VSCO) surges after a rating upgrade — plus more hot and not-so-hot stocks for 12/12/2025.
2 days ago•Jessie Moore
ASAN
VSCO
USAR
EVRG
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.